Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s EBITDA?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported EBITDA of -$55.93M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s EBITDA changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s EBITDA decreased by 19.4% year-over-year, from -$46.83M to -$55.93M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s EBITDA has grown at a 5.4% compound annual growth rate (CAGR), from -$242.08M to -$298.59M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude